Logo do repositório
 
Publicação

Omalizumab induced Takotsubo syndrome : case report

2019Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorAguiar-Ricardo, Inês
dc.contributor.authorNunes-Ferreira, Afonso
dc.contributor.authorRoda, Ângela
dc.contributor.authorRosario, Luis
dc.date.accessioned2019-11-04T15:57:54Z
dc.date.available2019-11-04T15:57:54Z
dc.date.issued2019
dc.description© The Author(s) 2019.The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.compt_PT
dc.description.abstractBackground: Omalizumab is a humanized monoclonal anti-immunoglobulin E antibody, approved for the treatment of spontaneous chronic urticaria, with high efficacy and an excellent safety profile. Although its adverse effects are rare, allergic reactions and cardiovascular events were previously described. Case summary: The authors describe the case of a 75-year-old woman, followed at the outpatient dermatology clinic due to spontaneous chronic urticaria, treated with omalizumab 300 mg every 4 weeks. After the 11th administration of omalizumab, the patient developed an episode of thoracalgia associated with electro- and echocardiographic abnormalities. Coronary angiogram excluded coronary artery disease, and left ventriculography demonstrated mid-apical akinesia and basal hyperkinesia, consistent with the Takotsubo syndrome (TS). Discussion: Takotsubo syndrome was already reported in association with other monoclonal antibodies. However, to our knowledge, this is the first case of TS following the administration of omalizumab.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuropean Heart Journal - Case Reports, Volume 3, Issue 1, March 2019, yty155pt_PT
dc.identifier.doi10.1093/ehjcr/yty155
dc.identifier.issn2514-2119
dc.identifier.urihttp://hdl.handle.net/10451/40043
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.relation.publisherversionhttps://academic.oup.com/ehjcrpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectTakotsubo syndromept_PT
dc.subjectOmalizumabpt_PT
dc.subjectCase reportpt_PT
dc.subjectLeft ventricular dysfunctionpt_PT
dc.titleOmalizumab induced Takotsubo syndrome : case reportpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPageyty155pt_PT
oaire.citation.titleEuropean Heart Journal: Case Reportspt_PT
oaire.citation.volume3pt_PT
person.familyNameAguiar-Ricardo
person.familyNameNunes-Ferreira
person.familyNameRosario
person.givenNameInês
person.givenNameAfonso
person.givenNameLuis
person.identifier.ciencia-idD012-F874-3DA7
person.identifier.ciencia-id0419-C014-BA22
person.identifier.ciencia-id9B19-8F5B-7207
person.identifier.orcid0000-0002-9951-1104
person.identifier.orcid0000-0002-2836-9497
person.identifier.orcid0000-0003-0014-1543
person.identifier.ridB-2252-2013
person.identifier.scopus-author-id6602614908
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication5dd978c7-1c24-4091-ae7d-406ea82c0a00
relation.isAuthorOfPublicationea30d6c6-61a5-4dc8-a175-d4b3631c168a
relation.isAuthorOfPublicationb0f83483-f787-4346-b2c1-e49a2d139790
relation.isAuthorOfPublication.latestForDiscoveryea30d6c6-61a5-4dc8-a175-d4b3631c168a

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Omalizumab.pdf
Tamanho:
346.14 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-CCUL-Artigos em Revistas Internacionais